Evidence map›Paper›PMID 42169655›Full record

ReviewMolecular medicine reports2026

Reprogramming of the hepatic ubiquitin‑immune axis: A unifying mechanism in liver disease progression (Review).

Yadi Ju, Xiaodan Chong, Weichen Ning, Yan Shi, Yangyang Li, Yihai Shi

Abstract readReview
In one paragraph

Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yadi Ju *School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai 200093, P.R. China.
Xiaodan Chong *Clinical Oncology Institute, Center for Translational Medicine, Naval Medical University, Shanghai 200433, P.R. China.
Weichen NingSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai 200093, P.R. China.
Yan ShiSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai 200093, P.R. China.
Yangyang LiClinical Oncology Institute, Center for Translational Medicine, Naval Medical University, Shanghai 200433, P.R. China.
Yihai ShiDepartment of Gastroenterology, Gongli Hospital, Shanghai 200135, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The progression of liver disease from steatosis to hepatocellular carcinoma has previously been interpreted as a sequential pathological continuum. In the present review, an integrated paradigm wherein this progression arises fundamentally from systematic reprogramming of the ubiquitin code within the hepatic microenvironment was proposed. Under sustained pathological stress, key E3 ligases and deubiquitinases undergo functional remodeling, transitioning from homeostatic guardians to pathogenic drivers of disease. The mechanism by which this reprogramming forms a central axis governing disease progression was systemically illustrated. During initiation, it disrupts inflammasome regulation and mitophagy; throughout progression, it dismantles immune tolerance and activates cell death pathways; and in advanced stages, it stabilizes oncoproteins, degrades tumor suppressors and facilitates immune evasion. Building upon this mechanistic model, novel therapeutic strategies aimed at achieving a functional reset of the dysregulated ubiquitin system via targeted protein degradation were further explored. This approach offers a transformative framework for intercepting the malignant progression of liver disease and presents new prospects for clinical intervention.

Indexed as

Carcinoma, HepatocellularLiverLiver DiseasesLiver NeoplasmsUbiquitinAnimalsDisease ProgressionHumansUbiquitinationUbiquitin-Protein LigasesUbiquitinUbiquitin-Protein Ligaseshepatocellular carcinomaimmune‑metabolic reprogrammingliver disease progressionubiquitin system

Identifiers

PMID42169655
PMCPMC13237522

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.